Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study.
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Carboplatin
/ administration & dosage
Carcinoma, Ovarian Epithelial
/ drug therapy
Chemotherapy, Adjuvant
Cohort Studies
Dose-Response Relationship, Drug
Drug Administration Schedule
Female
Humans
Middle Aged
Neoadjuvant Therapy
Ovarian Neoplasms
/ drug therapy
Paclitaxel
/ administration & dosage
Progression-Free Survival
Prospective Studies
Retrospective Studies
Young Adult
Adjuvant
Dose delays
Dose reductions
Ovarian cancer
Patient outcomes
Journal
Gynecologic oncology
ISSN: 1095-6859
Titre abrégé: Gynecol Oncol
Pays: United States
ID NLM: 0365304
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
31
01
2020
accepted:
25
04
2020
pubmed:
10
5
2020
medline:
11
2
2021
entrez:
9
5
2020
Statut:
ppublish
Résumé
To determine the impact of chemotherapy dose reductions and dose delays on progression-free survival (PFS) in women with ovarian cancer receiving first line chemotherapy in a real world prospective cohort study. Patients with newly diagnosed epithelial ovarian (or peritoneal, fallopian tube) cancer enrolled in a national Australian prospective study, OPAL, who commenced three-weekly carboplatin (AUC 5 or 6) and paclitaxel 175 mg/m 634 evaluable patients, 309 commenced CP and 325 DD-CP. Patient's age was similar in the two groups (median 62 years, range 21-79). All planned chemotherapy doses were completed by 66% vs 40% (p < 0.001) in the CP and DD-CP groups respectively. There was at least one treatment delay in 28% vs 58% (p < 0.001) in the CP and DD-CP groups, respectively, and 29% vs 49% (p < 0.001), respectively, required at least a 15% dose reduction for either carboplatin or paclitaxel. Median PFS was 29.2 [22.9, 43.8] and 21.5 [19.4, 23.1] months in the CP and DD-CP groups respectively. Adjusting for age, histology and FIGO stage PFS did not differ between treatment groups. Median PFS was similar in patients irrespective of dose reduction or dose delay. Patients receiving DD-CP required more dose reductions and delays due to haematological toxicities and lower completion rates than CP without significant difference in median PFS between CP and DD-CP. Median PFS was similar in patients irrespective of dose reduction or dose delay.
Identifiants
pubmed: 32381362
pii: S0090-8258(20)31016-7
doi: 10.1016/j.ygyno.2020.04.706
pii:
doi:
Substances chimiques
Carboplatin
BG3F62OND5
Paclitaxel
P88XT4IS4D
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
47-53Informations de copyright
Crown Copyright © 2020. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest A deFazio has received research grant support from AstraZeneca Australia. P Webb has received research grant from National Health and Medical Research Council of Australia and AstraZeneca Australia. M Friedlander has received research grants from AstraZeneca Australia, personal fees from AstraZeneca, personal fees from MSD, personal fees from Takeda, personal fees from Lilly, other from AstraZeneca, other from Abbvie.